Search results
Aug 9, 2024 · Scleroderma, or systemic sclerosis, is a chronic autoimmune disease characterized by skin hardening and internal organ involvement. This article provides a comprehensive overview of scleroderma, including its symptoms, causes, and treatment options.
Aug 4, 2024 · Care guide for Scleroderma. Includes: possible causes, signs and symptoms, standard treatment options and means of care and support.
13 hours ago · Background Current treatment for localized scleroderma (LS) has been shown to halt disease activity, but little is still known about patient experiences with these treatments, nor is there consensus about optimal measurement strategies for future clinical trials. Objective Conduct a scoping review of the literature for the types of outcomes and measures (i.e. clinician-, patient-, and ...
Aug 13, 2024 · Intravenous immunoglobulin (IVIG) eases skin, muscle and digestive symptoms in people with scleroderma (SSc), particularly when used as an add-on therapy, according to a recent review study. While no improvements were seen in respiratory function, IVIG still led to stabilization of these symptoms.
6 days ago · The basic principles of scleroderma, its manifestations, and treatment options. A detailed analysis of the symptoms for a better understanding of their impacts. The importance of emotional support and the value of support networks for living with resilience and hope.
Aug 11, 2024 · Using mice, lab-grown cells and clues from a related disorder, researchers have greatly increased understanding of the causes of systemic sclerosis, showing that a critical culprit is a...
People also ask
What are scleroderma guidelines?
How is scleroderma treated?
What causes scleroderma?
What are the different types of scleroderma?
Aug 14, 2024 · Describe the clinical characteristics of scleroderma patients that place them at high risk of developing PAH. Devise strategies to optimize screening and early detection of PAH in scleroderma patients. Develop best management practices to improve the care of patients with scleroderma-related PAH.
